ライフサイエンスコーパス: pseudomallei

1 g. PenA in B. cepacia complex and PenI in B. pseudomallei).

2 P) in a Gram-negative bacillus (Burkholderia pseudomallei).

3 y results guided soil sampling to isolate B. pseudomallei.

4 into a frequently overlooked reservoir of B. pseudomallei.

5 erall, 195 of 653 samples (29.7%) yielded B. pseudomallei.

6 tribution of NOD2 to the host response to B. pseudomallei.

7 th the NOD2 ligand, muramyl dipeptide, or B. pseudomallei.

8 ed against intraperitoneal challenge with B. pseudomallei.

9 tes when challenged with a lethal dose of B. pseudomallei.

10 ing severe Gram-negative sepsis caused by B. pseudomallei.

11 ethal challenge with B. thailandensis and B. pseudomallei.

12 d by the flagellated saprophyte Burkholderia pseudomallei.

13 nates were elevated in mice infected with B. pseudomallei.

14 elop chronic, subclinical infections with B. pseudomallei.

15 otection against infection with wild-type B. pseudomallei.

16 by the gram-negative bacterium Burkholderia pseudomallei.

17 contribute to the competitive fitness of B. pseudomallei.

18 hemical associations with the presence of B. pseudomallei.

19 nt role in the intracellular lifestyle of B. pseudomallei.

20 Burkholderia thailandensis and Burkholderia pseudomallei.

21 n in the intracellular pathogen Burkholderia pseudomallei.

22 s flagellar glycosylation and motility in B. pseudomallei.

23 e role of these systems in the biology of B. pseudomallei.

24 e with 100% lethal doses of B. mallei and B. pseudomallei.

25 lected one for the diagnosis of Burkholderia Pseudomallei.

26 thogens Burkholderia mallei and Burkholderia pseudomallei.

27 mparable to signaling induced by virulent B. pseudomallei.

28 idase (GPx) of PMNs after exposed to live B. pseudomallei.

29 h as Francisella tularensis and Burkholderia pseudomallei.

30 about secretion systems of B. mallei and B. pseudomallei.

31 base with corresponding information about B. pseudomallei.

32 the Gram-negative soil bacillus Burkholderia pseudomallei.

33 wth characteristics of a recently created B. pseudomallei 1026b Deltaasd mutant in vitro, in a cell m

34 s a model, we show that a CDI system from B. pseudomallei 1026b mediates CDI and is capable of delive

35 /c mice to various amounts of aerosolized B. pseudomallei 1026b to determine lethality.

36 from Escherichia coli EC869 and Burkholderia pseudomallei 1026b.

37 monkeys (AGMs) was exposed to aerosolized B. pseudomallei 1026b.

38 CT(E479) is another CDI toxin domain from B. pseudomallei 1026b.

39 ns were Escherichia coli (28%), Burkholderia pseudomallei (11%), Klebsiella pneumoniae (9%), and Stap

40 ngi, MB bottles improved the detection of B. pseudomallei (27% [MB] versus 8% [F]; P < 0.0001), with

41 sonance (NMR) spectroscopy, we found that B. pseudomallei 4095a and 4095c OPS antigens exhibited subs

42 Gram-negative sepsis caused by Burkholderia pseudomallei, a "Tier 1" biothreat agent and the causati

43 fungal infections and for infection with B. pseudomallei, a common cause of septicemia in Thailand.

44 Burkholderia pseudomallei, a facultative intracellular bacterium, cau

45 Burkholderia pseudomallei, a highly pathogenic bacterium that causes

46 h the highly virulent bacterium Burkholderia pseudomallei, a particularly antimicrobial-resistant pat

47 ve shown that BipC was capable of delayed B. pseudomallei actin-based motility.

48 for the rapid in vivo diversification of B. pseudomallei after inoculation and systemic spread.

49 glutaryl-CoA dehydrogenase from Burkholderia pseudomallei against 48 different reagents; each reagent

50 cells following infection with Burkholderia pseudomallei, an intracellular bacterial pathogen and th

51 Burkholderia pseudomallei and B. mallei are bacterial pathogens that

52 , unique and shared virulence features of B. pseudomallei and B. mallei are discussed.

53 In contrast, B. pseudomallei and B. mallei BimA mimic host Ena/VASP acti

54 mono- and disaccharidic fragments of the B. pseudomallei and B. mallei CPS repeating unit is reporte

55 hes and contribute to the pathogenesis of B. pseudomallei and B. mallei.

56 summary, neutrophils can efficiently kill B. pseudomallei and B. thailandensis that possess a critica

57 hydrate covalently linked to a protein in B. pseudomallei and B. thailandensis, and it suggests new a

58 PL as a critical virulence determinant of B. pseudomallei and B. thailandensis, further highlighting

59 ent was essential for cell-cell spread by B. pseudomallei and B. thailandensis, neither BimA-mediated

60 g exopolysaccharide produced by Burkholderia pseudomallei and bacteria of the B. cepacia complex is d

61 The global distribution of B. pseudomallei and burden of melioidosis, however, remain

62 Burkholderia pseudomallei and Burkholderia mallei are closely related

63 Burkholderia pseudomallei and Burkholderia mallei are potential biote

64 the closely related pathogenic Burkholderia pseudomallei and Burkholderia mallei.

65 Burkholderia pseudomallei and Burkholderia thailandensis are related

66 ultative intracellular bacteria Burkholderia pseudomallei and Burkholderia thailandensis.

67 l cases and the presence of environmental B. pseudomallei and combine this in a formal modelling fram

68 A bipC TTSS-3-deficient strain of B. pseudomallei and complemented strains were generated to

69 hogenic, select-agent-excluded strains of B. pseudomallei and covalently linked to carrier proteins.

70 sis results from infection with Burkholderia pseudomallei and is associated with case-fatality rates

71 that is caused by the bacterium Burkholderia pseudomallei and is underreported in many countries wher

72 ionally interchangeable between Burkholderia pseudomallei and its relatives B. mallei, B. oklahomensi

73 Mice were intranasally infected with live B. pseudomallei and killed after 24, 48, or 72 hours for ha

74 ce were intranasally infected with viable B. pseudomallei and killed after 24, 48, or 72 hours for ha

75 tranasally infected with viable Burkholderia pseudomallei and killed after 24, 48, or 72 hrs for harv

76 Thailand was co-cultured with B. pseudomallei and production of IL-10 and IFN-gamma detec

77 VgrG5 facilitates intercellular spread by B. pseudomallei and related species following injection acr

78 upon subsequent infection with Burkholderia pseudomallei and Salmonella enterica HMBA treatment was

79 The global distribution of B. pseudomallei and the burden of melioidosis, however, rem

80 f the potential biothreat agent Burkholderia pseudomallei and the closely related but nonpathogenic B

81 eloped to monitor levels of resistance of B. pseudomallei and the closely related nearly avirulent sp

82 d to investigate cross-reactivity between B. pseudomallei and the related Burkholderia species associ

83 The human pathogen Burkholderia pseudomallei and the related species Burkholderia thaila

84 cases, and the presence of environmental B. pseudomallei, and combine this in a formal modelling fra

85 rthologs of these genes were disrupted in B. pseudomallei, and nearly all mutants had similarly decre

86 ignificant protection from challenge with B. pseudomallei, and protection was associated with a signi

87 gene expression and stress adaptation in B. pseudomallei, and the DeltarelA DeltaspoT mutant may be

88 No coworkers had detectable anti-B. pseudomallei antibody, whereas seropositive results amon

89 B. mallei and B. pseudomallei are closely related genetically; B. mallei

90 urkholderia cepacia complex and Burkholderia pseudomallei are opportunistic human pathogens.

91 Burkholderia mallei and B. pseudomallei are the causative agents of glanders and me

92 Due to the potential malicious use of B. pseudomallei as well as its impact on public health in r

93 gates of antigen-induced immunity against B. pseudomallei as well as provide valuable insights toward

94 25 x 25 m) should be sufficient to detect B. pseudomallei at a given location if samples are taken at

95 ltured soil from a rice field in Laos for B. pseudomallei at different depths on 4 occasions over a 1

96 Burkholderia spp. that includes Burkholderia pseudomallei, B. mallei, and B. thailandensis.

97 This global survey of the QS regulons of B. pseudomallei, B. thailandensis, and B. mallei serves as

98 quences of 15 strains of B. oklahomensis, B. pseudomallei, B. thailandensis, and B. ubonensis to an a

99 e, we identify 10 distinct CDI systems in B. pseudomallei based on polymorphisms within the cdiA-CT/c

100 pidly recognizing isolates suspicious for B. pseudomallei, be able to safely perform necessary rule-o

101 Burkholderia pseudomallei (Bp) and Burkholderia mallei (Bm), the etio

102 Burkholderia pseudomallei (Bp) is the causative agent of the infectio

103 , antibiotic-resistant pathogen Burkholderia pseudomallei (BP).

104 in) from S. typhimurium (PrgJ), Burkholderia pseudomallei (BsaK), Escherichia coli (EprJ and EscI), S

105 Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholder

106 densis was more readily phagocytosed than B. pseudomallei, but both displayed similar rates of persis

107 ve cell mediated immune responses against B. pseudomallei, but may also moderate the pathological eff

108 allei evolved from an ancestral strain of B. pseudomallei by genome reduction and adaptation to an ob

109 tested for evidence of prior exposure to B. pseudomallei by indirect hemagglutination assay.

110 ction induced by flagellin or heat-killed B. pseudomallei by TLR5(1174C)>T genotype in healthy subjec

111 Human infections with B. pseudomallei (called melioidosis) present as a range of

112 B. pseudomallei capsular polysaccharide (CPS) I comprises u

113 Burkholderia mallei and B. pseudomallei cause glanders and melioidosis, respectivel

114 The environmental bacterium Burkholderia pseudomallei causes an estimated 165,000 cases of human

115 m and potential biothreat agent Burkholderia pseudomallei causes melioidosis, an often fatal infectio

116 Burkholderia pseudomallei causes the disease melioidosis in humans an

117 Infection with Burkholderia pseudomallei causes the disease melioidosis, which often

118 Biochemical analysis of three B. pseudomallei CdiA-CTs revealed that each protein possess

119 rmation, which were observed in wild-type B. pseudomallei cell infections.

120 ivity of detection and recovery of viable B. pseudomallei cells from small volumes (0.45 ml) of urine

121 nclude Acinetobacter baumannii, Burkholderia pseudomallei, Chlamydia trachomatis, Escherichia coli, K

122 Deficiency of Nrf2 improved B. pseudomallei clearance by macrophages, whereas Nrf2 acti

123 fection caused by the bacterium Burkholderia pseudomallei Clinical diagnosis of melioidosis can be ch

124 AhpC is virtually invariant among global B. pseudomallei clinical isolates, a Cambodian isolate vari

125 ularensis, Burkholderia mallei, Burkholderia pseudomallei, Clostridium botulinum, Brucella melitensis

126 % to 75% for B. anthracis, Y. pestis, and B. pseudomallei compared to conventional methods.

127 an neutrophils to control highly virulent B. pseudomallei compared to the relatively avirulent, acaps

128 anthracis, Yersinia pestis, or Burkholderia pseudomallei Conventional susceptibility tests require 1

129 Thus, the B. pseudomallei Deltaasd mutant may be a promising live att

130 Further characterization of the B. pseudomallei Deltaasd mutant revealed a marked decrease

131 pernatants of B. pseudomallei MSHR668 and B. pseudomallei DeltagspD grown in rich and minimal media.

132 The B. pseudomallei DeltarelA DeltaspoT mutant displayed a defe

133 Mutational analysis of wild-type B. pseudomallei demonstrated that ceftazidime resistance wa

134 The FCR method showed greater B. pseudomallei detection sensitivity than conventional uri

135 Detection of B. pseudomallei DNA or recovery of the pathogen by culture

136 ice treated with doxycycline survived and B. pseudomallei DNA was not amplified from the lungs or spl

137 We demonstrate that B. pseudomallei down-regulation of ELT-2 targets is associa

138 The bsa locus of Burkholderia pseudomallei encodes several proteins that are component

139 ams targeting both at-risk individuals in B. pseudomallei endemic regions as well as CF patients.

140 gram-negative sepsis caused by Burkholderia pseudomallei, endogenous tissue-type plasminogen activat

141 than the 30 cm currently recommended for B. pseudomallei environmental sampling.

142 rain generated by deletion of BPSS1823 in B. pseudomallei exhibited a reduced ability to survive with

143 o encompass strong CD4 T cell epitopes in B. pseudomallei-exposed individuals and in HLA transgenic m

144 B. pseudomallei expresses three serologically distinct LPS

145 The B. pseudomallei flagellar protein FliC is strongly seroreac

146 strains of each species demonstrated that B. pseudomallei flagellin proteins were modified with a gly

147 B. pseudomallei FliC contained several peptide sequences wi

148 T cell hybridomas against an immunogenic B. pseudomallei FliC epitope also cross-reacted with orthol

149 We assessed B. pseudomallei FliC peptide binding affinity to multiple H

150 ons suggest that some factors required by B. pseudomallei for resistance to environmental phagocytes

151 or clinical sample positive for Burkholderia pseudomallei from 2001 to 2012.

152 Taken together, isolation of B. pseudomallei from a soil sample and high seropositivity

153 was the central step in dissemination of B. pseudomallei from the lungs as well as in the establishm

154 enes may be remnants of the QS network in B. pseudomallei from which this host-adapted pathogen evolv

155 egulates the expression of ~30 additional B. pseudomallei genes, including some that may confer produ

156 sis of this structure and the activity of B. pseudomallei GmhA mutants.

157 Pseudomallei group Burkholderia are emerging pathogens w

158 Pseudomallei group Burkholderia species are facultative

159 ient with a clonal infection of Burkholderia pseudomallei had subpopulations with ceftazidime and amo

160 disease caused by the bacterium Burkholderia pseudomallei, has a wide spectrum of clinical manifestat

161 ed to prepare highly purified recombinant B. pseudomallei Hcp1 and TssM proteins.

162 Human OECs killed >90% of the B. pseudomallei in a CPS I-independent manner and exhibited

163 However, culture of B. pseudomallei in environmental samples is difficult and l

164 measured NF-kappaB activation induced by B. pseudomallei in human embryonic kidney-293 cells transfe

165 tis and B. pseudomallei One exception was B. pseudomallei in the presence of ceftazidime, which requi

166 A and Bp340DeltabcaB mutants to wild-type B. pseudomallei in vitro demonstrated similar levels of adh

167 d diabetic individuals infected with live B. pseudomallei in vitro showed lower free glutathione (GSH

168 althy individuals and improved killing of B. pseudomallei in vitro.

169 s the only Hcp constitutively produced by B. pseudomallei in vitro; however, it was not exported to t

170 protective immunity against B. mallei and B. pseudomallei, including antigen discovery.

171 B. pseudomallei induced lower monocyte-normalized levels of

172 ells transfected with TLR5 and found that B. pseudomallei induced TLR5(1174C)- but not TLR5(1174T)-de

173 We found that B. pseudomallei-infected PBMCs from diabetic patients were

174 The unfavorable outcome of B. pseudomallei infection after HO-1 induction was associat

175 e demonstrated enhanced susceptibility to B. pseudomallei infection compared with wild type mice as e

176 eins, but its role in the pathogenesis of B. pseudomallei infection is not well understood.

177 tes effective protective immunity against B. pseudomallei infection remains incomplete.

178 sights into the host defense responses to B. pseudomallei infection within an intact host, we analyze

179 er explore the role of the OM response to B. pseudomallei infection, we infected human olfactory ensh

180 induced protective immunity against acute B. pseudomallei infection.

181 elioidosis, a disease caused by Burkholderia pseudomallei infection.

182 ontribute to the pathogenesis observed in B. pseudomallei infection.

183 r biliverdin, ferrous iron, and CO during B. pseudomallei infection.

184 susceptibility of diabetic individuals to B. pseudomallei infection.

185 ified calprotectin as a lead biomarker of B. pseudomallei infections and examined correlations betwee

186 neutrophils are important for controlling B. pseudomallei infections, however few details are known r

187 ost-B. mallei interactions and 2,286 host-B. pseudomallei interactions.

188 th American isolates with introduction of B. pseudomallei into the Americas between 1650 and 1850, pr

189 Furthermore, we show that B. pseudomallei invades fibroblasts and keratinocytes and s

190 Burkholderia pseudomallei is a category B pathogen and the causative

191 Burkholderia pseudomallei is a CDC tier 1 select agent that causes me

192 Burkholderia pseudomallei is a Gram-negative soil bacterium and the c

193 Burkholderia pseudomallei is a Gram-negative soil bacterium that infe

194 Burkholderia pseudomallei is a tier 1 select agent and the causative

195 Burkholderia pseudomallei is a tier 1 select agent, and the causative

196 Burkholderia pseudomallei is an emerging bacterial pathogen and categ

197 B. pseudomallei is an encapsulated bacterium that can infec

198 relatives with very different lifestyles: B. pseudomallei is an opportunistic pathogen, B. thailanden

199 B. pseudomallei is classed as a tier 1 select agent by the

200 on of a group 3 polysaccharide capsule in B. pseudomallei is essential for virulence.

201 ere, the structure of GmhA from Burkholderia pseudomallei is reported.

202 alkyl hydroperoxidase reductase (AhpC) of B. pseudomallei is strongly immunogenic for T cells of 'hum

203 Burkholderia pseudomallei is the causative agent of melioidosis and i

204 Burkholderia pseudomallei is the causative agent of melioidosis chara

205 Burkholderia pseudomallei is the causative agent of melioidosis, a di

206 Burkholderia pseudomallei is the causative agent of melioidosis.

207 by the Gram-negative bacterium Burkholderia pseudomallei, is a frequent cause of pneumosepsis in Sou

208 Melioidosis, caused by Burkholderia pseudomallei, is a potentially lethal infection with no

209 idosis, caused by the bacterium Burkholderia pseudomallei, is an often severe infection that regularl

210 ith the environmental bacterium Burkholderia pseudomallei, is being recognised increasingly frequentl

211 ioidosis, an infectious disease caused by B. pseudomallei, is diabetes mellitus.

212 d by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure.

213 Melioidosis, caused by Burkholderia pseudomallei, is endemic in northeastern Thailand and No

214 prove when the infecting agent, Burkholderia pseudomallei, is rapidly detected and identified by labo

215 n/immunity protein complex from Burkholderia pseudomallei isolate E479.

216 uate 69 independent colonies of Burkholderia pseudomallei isolated from seven body sites of a patient

217 Twelve Burkholderia pseudomallei isolates collected over a 32-month period f

218 We used whole genome sequences of 469 B. pseudomallei isolates from 30 countries collected over 7

219 B. pseudomallei isolates from the property's groundwater su

220 We observed that primary clinical B. pseudomallei isolates with mucoid and nonmucoid colony m

221 Burkholderia pseudomallei isolates with shared multilocus sequence ty

222 levels of protection against a wild-type B. pseudomallei K96243 challenge.

223 ations outside the OA subset in Burkholderia pseudomallei K96243 for comparison.

224 The Burkholderia pseudomallei K96243 genome encodes six type VI secretion

225 Mice immunized with the B. pseudomallei K96243 mutants lacking a functional copy of

226 that inactivating gmhA, wcbJ, and wcbN in B. pseudomallei K96243 retains the immunogenic integrity of

227 nvolved in LPS synthesis was performed in B. pseudomallei K96243.

228 computationally derived information about B. pseudomallei K96243.

229 O-releasing molecule CORM-2 increases the B. pseudomallei load in macrophages and mice.

230 B. pseudomallei locus tags within the full text and tables

231 h a combination of CPS2B1 and recombinant B. pseudomallei LolC, rather than with CPS2B1 or LolC indiv

232 Thus, our data suggest that the B. pseudomallei-mediated induction of HO-1 and the release

233 ith the Gram-negative bacterium Burkholderia pseudomallei (melioidosis) are associated with high mort

234 Following exposure to B. pseudomallei, mice lacking the lectin-like domain of thr

235 y proteins present in the supernatants of B. pseudomallei MSHR668 and B. pseudomallei DeltagspD grown

236 The secretion profiles of B. pseudomallei MSHR668 and its T2SS mutants were noticeabl

237 ter low-dose inoculation with aerosolized B. pseudomallei, Nod2-deficient mice showed impaired clinic

238 Although unrelated in sequence, the two B. pseudomallei nuclease domains share similar folds and ac

239 r B. anthracis and <6 h for Y. pestis and B. pseudomallei One exception was B. pseudomallei in the pr

240 Our studies indicate that B. pseudomallei OPS undergoes antigenic variation and sugge

241 ing with clinical isolates suspicious for B. pseudomallei or clinical specimens from suspected melioi

242 causative agent of melioidosis, Burkholderia pseudomallei Passive-transfer experiments also revealed

243 rulence with roles in different stages of B. pseudomallei pathogenesis, including extracellular and i

244 determine its role(s) in the virulence of B. pseudomallei pathogenesis.

245 tle is known about the molecular basis of B. pseudomallei pathogenicity, in part because of the lack

246 n reduced the survival of intramacrophage B. pseudomallei Pharmacological administration of cobalt pr

247 The human pathogen Burkholderia pseudomallei possesses multiple type III secretion syste

248 lei proteins, and new information for 281 B. pseudomallei proteins associated with 5 secretion system

249 ein microarray containing 1,205 Burkholderia pseudomallei proteins, probed it with 88 melioidosis pat

250 ived a lethal inhalational challenge with B. pseudomallei Remarkably, 70% of the survivors had no cul

251 sults and decrease the number of negative B. pseudomallei reports that are currently observed from ur

252 rotein of unknown function from Burkholderia pseudomallei, reveals a similarity to Escherichia coli c

253 ic mechanisms of action for B. mallei and B. pseudomallei secretion system proteins inferred from the

254 virulence attenuation experiments for 61 B. pseudomallei secretion system proteins.

255 e, Wong et al. (2015) show that Burkholderia pseudomallei senses host cytosolic glutathione, a low-mo

256 mediated NF-kappaB activation induced by B. pseudomallei stimulation of HEK293 cells.

257 The genome of B. pseudomallei strain 1026b encodes nine putative trimeric

258 en reading frame Bp1026b_II1054 (bcaA) in B. pseudomallei strain 1026b is predicted to encode a class

259 ted to intranasal challenge with virulent B. pseudomallei strain 1026b.

260 There is currently no attenuated B. pseudomallei strain available that is excluded from sele

261 , we created a relA spoT double mutant in B. pseudomallei strain K96243, which lacks (p)ppGpp-synthes

262 ct Agent-excluded purM deletion mutant of B. pseudomallei (strain Bp82) and then subjected to intrana

263 Bp190, which are DeltapurM derivatives of B. pseudomallei strains 1026b and K96243 that are deficient

264 tagenesis and secretion experiments using B. pseudomallei strains engineered to express T6SS-5 in vit

265 Nearly all B. pseudomallei strains sequenced to date (> 85 isolates) c

266 ivering CdiA-CT toxins derived from other B. pseudomallei strains.

267 immunity against challenge with wild-type B. pseudomallei, suggesting that the genes identified in ou

268 CPS I improved B. pseudomallei survival in vivo and triggered multiple cyt

269 , these findings show a role for CPS I in B. pseudomallei survival in vivo following inhalation infec

270 he first in-depth characterization of the B. pseudomallei T2SS secretome.

271 One of these, the B. pseudomallei T3SS2 (T3SS2(bp)) gene cluster, which appar

272 e on GSH and PMN functions in response to B. pseudomallei that may contribute to the susceptibility o

273 DNA from eight strains of B. pseudomallei that were spiked into synthetic urine at lo

274 gen and culture filtrate [CF] antigen) of B. pseudomallei The ELISAs were evaluated using serum sampl

275 tanding of adaptive immunity to Burkholderia pseudomallei, the causative agent of melioidosis that is

276 Burkholderia pseudomallei, the causative agent of melioidosis, has co

277 Burkholderia pseudomallei, the causative agent of melioidosis, is an

278 Burkholderia pseudomallei, the causative agent of melioidosis, is rec

279 Burkholderia pseudomallei, the cause of serious and life-threatening

280 Burkholderia pseudomallei, the etiologic agent of melioidosis, causes

281 Burkholderia pseudomallei, the etiologic agent of melioidosis, is a C

282 Burkholderia pseudomallei, the etiologic agent of melioidosis, is an

283 cretion system proteins for B. mallei and B. pseudomallei, their pathogenic mechanisms of action, and

284 During infection with Burkholderia pseudomallei, tissue-type plasminogen activator-deficien

285 We report the capacity of B. pseudomallei to enter, efficiently replicate in, and med

286 We used aerosol delivery of B. pseudomallei to establish respiratory infection in mice

287 infected with either high or low doses of B. pseudomallei to generate either acute, chronic, or laten

288 /-)) mice were intranasally infected with B. pseudomallei to induce severe pneumosepsis (melioidosis)

289 Degradation of ELT-2 requires the B. pseudomallei type III secretion system.

290 erns for fighting diseases like Burkholderia pseudomallei using biomarkers involves two key issues.

291 suggesting that BPSS1823 is important for B. pseudomallei virulence.

292 odel system for facilitating inquiry into B. pseudomallei virulence.

293 eature of the transcriptional response to B. pseudomallei was a progressive increase in the proportio

294 B. pseudomallei was associated with a high soil water conte

295 piric use of antibiotics not specific for B. pseudomallei was associated with increased risk of death

296 A higher prevalence of B. pseudomallei was found at soil depths greater than the 3

297 Burkholderia pseudomallei was isolated from soil collected in the nei

298 heptan capsular polysaccharide (CPS) from B. pseudomallei was purified, chemically activated, and cov

299 significantly more C3 on its surface than B. pseudomallei, whose polysaccharide capsule significantly

300 roteins exported by these systems provide B. pseudomallei with a growth advantage in vitro and in viv